A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients. Issue 13 (5th July 2022)

• Record Type: Journal Article
• Authors: Zheng, Xiang; Zhang, Weijie; Zhou, Hua; Cao, Ronghua; Shou, Zhangfei; Zhang, Shuwei; Cheng, Ying; Chen, Xuchun; Ding, Chenguang; Tang, Zuofu; Li, Ning; Shi, Shaohua; Zhou, Qiang; Chen, Qiuyuan; Chen, Gang; Chen, Zheng; Zhou, Peijun; Hu, Xiaopeng; Zhang, Xiaodong; Na, Ning; Wang, Wei
• Editors: Ji, Yuanyuan
• Is Part Of: Chinese medical journal. Volume 135:Issue 13(2022)
• Page Start: 1597
• Page End: 1603
• Publication Date: 2022-07-05
• Subjects: Calcineurin inhibitor -- Conversion -- Rapamycin -- Renal transplantation -- Sirolimus; Medicine -- Periodicals; Medicine, Oriental -- Periodicals; Medicine; Medicine, Oriental; Medicine; Medicine, East Asian Traditional; Periodicals; Electronic journals; 610.5
• DOI: 10.1097/CM9.0000000000001866
• Languages: English
• ISSNs: 0366-6999

Abstract

Abstract: Background: The calcineurin inhibitor (CNI)-based immune maintenance regimen that is commonly used after renal transplantation has greatly improved early graft survival after transplantation; however, the long-term prognosis of grafts has not been significantly improved. The nephrotoxicity of CNI drugs is one of the main risk factors for the poor long-term prognosis of grafts. Sirolimus (SRL) has been employed as an immunosuppressant in clinical practice for over 20 years and has been found to have no nephrotoxic effects on grafts. Presently, the regimen and timing of SRL application after renal transplantation vary, and clinical data are scarce. Multicenter prospective randomized controlled studies are particularly rare. This study aims to investigate the effects of early conversion to a low-dose CNI combined with SRL on the long-term prognosis of renal transplantation. Methods: Patients who receive four weeks of a standard regimen with CNI + mycophenolic acid (MPA) + glucocorticoid after renal transplantation in multiple transplant centers across China will be included in this study. At week 5, after the operation, patients in the experimental group will receive an additional administration of SRL, a reduction in the CNI drug doses, withdrawal of MPA medication, and maintenance of glucocorticoids. In addition, patients in the control group will receive the maintained standard of care. The patients' vital signs, routine blood tests, routine urine tests, blood biochemistry, serum creatinine, BK virus (BKV)/ cytomegalovirus (CMV), and trough concentrations of CNI drugs and SRL at the baseline and weeks 12, 24, 36, 48, 72, and 104 after conversion will be recorded. Patient survival, graft survival, and estimated glomerular filtration rate will be calculated, and concomitant medications and adverse events will also be recorded. Conclusion: The study data will be utilized to evaluate the efficacy and safety of early conversion to low-dose CNIs combined with SRL in renal transplant patients. Trial registration: Chinese Clinical Trial Registry, ChiCTR1800017277.